2025.09.02 从行业分布来看，社保基金此次新进和增持的个股主要集中在生物医药、计算机、电子等热门赛道，也 恰恰是国家战略支持的重点方向，也是经济转型升级的关键领域。这一投资动向引起了市场广泛关注。 作为具备长期稳定盈利能力的社保基金，其每一步调仓都蕴含着深层的战略思考。那么，社保基金大幅 增持科技股背后，究竟有着怎样的逻辑？ 偏爱医药、计算机 社保基金素以"稳健"著称，其投资风格一向谨慎，注重价值投资和长期回报。近年来，这一稳健投资者 加大了对科技创新企业的布局力度。 截至二季度末，社保基金持有77家科创板上市公司股票，主要集中在电子、生物医药、机械设备、计算 机四大行业，分别有20家、13家、10家、11家公司。 持股数量方面，社保基金持股达到且超过1000万股的共有7只，持有传音控股（688036.SH）3826.4万 股，位居第一，其次为西部超导（688122.SH），为2058.1万股；持有珠海冠宇（688772.SH）、铁建重 工（688425.SH）、中科星图（688568.SH）、三一重能（688349.SH）、聚合材料（688503.SH）的股 份数量也超过1000万股。 从社保基金的 ...

Core Viewpoint - The company has announced a delay in the completion of its research and development center project, extending the timeline to December 2026 due to adjustments in product development planning influenced by industry policies [1][5][6]. Fundraising Overview - The company raised a total of RMB 150,002.23 million by issuing 41.4142 million shares at a price of RMB 36.22 per share, with a net amount of RMB 138,228.49 million after deducting related expenses [1][2]. Fund Utilization and Project Adjustment - The company adjusted the planned investment amounts for its fundraising projects due to discrepancies between the originally planned and actual amounts raised, with total project investments amounting to RMB 203,694.15 million and adjusted investments of RMB 188,066.62 million [2][3]. Delay Details and Reasons - The delay in the R&D center project is attributed to the impact of orthopedic centralized procurement policies, necessitating adjustments in product development strategies. The project has expanded to include new locations in Shanghai and Wuhan, focusing on high-value product lines such as spinal minimally invasive techniques and 3D printing [4][5]. Impact on Operations - The delay in project completion is a cautious decision based on actual implementation needs and does not affect the project's investment content, total investment, or implementation entity. It is aligned with the company's operational status and long-term development plans [5][6][7]. Review Procedures - The board and supervisory committee approved the delay without requiring a shareholder meeting, confirming that the decision adheres to relevant regulations and does not harm shareholder interests [6][7].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Weigao Orthopedics in the medical device industry, noting its current stock price and market capitalization [1][2] - As of August 15, Weigao Orthopedics closed at 31.3 yuan, with a PE ratio of 52.03 and a total market value of 12.52 billion yuan [1] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, positioning Weigao Orthopedics at the 86th rank within the industry [1][2] Group 2 - The company reported a revenue of 290 million yuan for Q1 2025, reflecting a year-on-year decrease of 16.59%, while net profit was 51.79 million yuan, showing a year-on-year increase of 48.37% [1] - The gross profit margin for Weigao Orthopedics stands at 63.68% [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents, indicating a strong focus on innovation in orthopedic medical devices [1]

Core Viewpoint - Weigao Orthopedics' stock closed at 30.83 yuan, down 2.99%, with a rolling PE ratio of 51.25 times, and a total market value of 12.332 billion yuan [1] Company Summary - Weigao Orthopedics specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments, making it a leading domestic orthopedic enterprise with the most comprehensive product variety [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] - For Q1 2025, the company reported revenue of 290 million yuan, a year-on-year decrease of 16.59%, and a net profit of 51.789 million yuan, a year-on-year increase of 48.37%, with a gross profit margin of 63.68% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Weigao Orthopedics at the 87th position in the industry [1] - The industry average market value is 11.792 billion yuan, while the median is 5.679 billion yuan [2]

8月12日，威高骨科今日收盘32.21元，上涨1.35%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到53.54倍，创353天以来新低，总市值128.84亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.90亿元，同比-16.59%；净利润5178.90万元， 同比48.37%，销售毛利率63.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13威高骨科53.5457.583.22128.84亿行业平均 57.5153.344.97120.28亿行业中值41.2539.962.9558.75亿1九安医疗11.2611.380.89189.95亿2英科医疗 15.0516.231.34237.81亿3山东药玻16.1716.221.86152.96亿4新华医疗16.9415.701.38108.60亿5振德医疗 17.3716.371.1063.04亿6奥美医疗17.5417.191.8063.39亿7九强生物17.9216.672.2088.77亿8康德莱 18.7518.761.5540.40亿9维力医疗18.7920.082.3644.05亿10奥泰生物19. ...

Core Viewpoint - Weigao Orthopedics has a closing price of 31.78 yuan, with a PE ratio of 52.83, marking a new low in 208 days, and a total market capitalization of 12.712 billion yuan [1] Group 1: Company Overview - Weigao Orthopedics specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments, making it a leading domestic enterprise in the orthopedic field [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] Group 2: Financial Performance - In the first quarter of 2025, Weigao Orthopedics reported an operating income of 290 million yuan, a year-on-year decrease of 16.59%, while net profit reached 51.789 million yuan, an increase of 48.37%, with a gross profit margin of 63.68% [1] Group 3: Shareholder Information - As of March 31, 2025, Weigao Orthopedics had 8,904 shareholders, a decrease of 302 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 4: Industry Comparison - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Weigao Orthopedics at the 86th position in the industry ranking [1][2]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Weigao Orthopedics, noting its stock price increase and current valuation metrics [1][2] - As of August 7, Weigao Orthopedics closed at 30.87 yuan, with a PE ratio of 51.31 times and a total market capitalization of 12.348 billion yuan [1] - The company ranks 86th in the medical device industry, which has an average PE ratio of 54.79 times and a median of 37.86 times [1][2] Group 2 - Weigao Orthopedics specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] - In the first quarter of 2025, the company reported a revenue of 290 million yuan, a year-on-year decrease of 16.59%, while net profit was 51.789 million yuan, reflecting a year-on-year increase of 48.37% with a gross margin of 63.68% [1]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Weigao Orthopedics, noting its stock price increase and current valuation metrics [1][2] - As of August 4, Weigao Orthopedics closed at 31.39 yuan, with a 6.08% increase, and a rolling PE ratio of 52.18, marking a new low in 203 days, with a total market capitalization of 12.556 billion yuan [1] - The company ranks 87th in the medical device industry, which has an average PE of 54.32 and a median of 38.11 [1][2] Group 2 - Weigao Orthopedics specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments, making it a leading domestic enterprise in terms of product variety and scale [1] - The company holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] - In the first quarter of 2025, Weigao Orthopedics reported a revenue of 290 million yuan, a year-on-year decrease of 16.59%, while net profit reached 51.789 million yuan, reflecting a year-on-year increase of 48.37%, with a gross margin of 63.68% [1]

7月28日，威高骨科今日收盘29.38元，上涨2.26%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到48.84倍，创78天以来新低，总市值117.52亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13威高骨科48.8452.522.93117.52亿行业平均 55.2850.194.76115.43亿行业中值38.0638.632.7156.35亿1九安医疗11.0111.130.87185.78亿2英科医疗 13.3414.381.19210.81亿3新华医疗15.4114.281.2698.77亿4振德医疗16.1715.241.0358.70亿5奥美医疗 16.2315.911.6758.64亿6山东药玻16.2516.301.87153.69亿7康德莱16.9917.001.4136.60亿8九强生物 17.5016.272.1486.66亿9奥泰生物18.0419.021.4657.52亿10维力医疗18.2118.932.1441.53亿11鱼跃医疗 20.0319.642.71354.68亿12三鑫医疗20.0520.053.3045.61亿 来源：金融界 山东 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Weigao Orthopedics, noting its stock price increase and current valuation metrics [1][2] - As of July 24, Weigao Orthopedics closed at 28.42 yuan, with a 4.26% increase, and a rolling PE ratio of 47.24, marking a new low in 76 days, with a total market capitalization of 11.368 billion yuan [1] - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, placing Weigao Orthopedics at the 85th position in the industry ranking [1][2] Group 2 - The company specializes in a wide range of orthopedic products, including spinal, trauma, joint, sports medicine, bone repair materials, tissue repair, and surgical instruments, making it a leading domestic enterprise in the orthopedic sector [1] - Weigao Orthopedics holds a total of 371 patents, including 86 invention patents and 266 utility model patents [1] - In the first quarter of 2025, the company reported a revenue of 290 million yuan, a year-on-year decrease of 16.59%, while net profit reached 51.789 million yuan, reflecting a year-on-year increase of 48.37%, with a gross profit margin of 63.68% [1]